Prevention of chronic kidney disease progression in patients with acute decompensation of chronic heart failure
https://doi.org/10.15829/1560-4071-2019-3-76-81
Abstract
Aim. To assess the efficiency of the program of prevention of chronic kidney disease (CKD) progression in patients with acute decompensation of chronic heart failure (CHF). The program included the use of nitrendipine, a calcium channel antagonist, and the replacement of single intravenous bolus dosing of furosemide with a prolonged intravenous infusion in the early stage of the disease.
Material and methods. One hundred twenty five patients with decompensation of CHF were examined and divided into 2 groups. Group 1 received standard therapy. In the group 2, an additional prevention program was carried out. The criterion of CKD progression was the change in glomerular filtration rate (GFR) in accordance with the KDIGO guidelines (2012). GFR was calculated by two methods: serum creatinine and cystatin C levels. The parameters were monitored and compared with baseline levels at admission to the hospital and on the 10th day of therapy. For the initial level was taken the patient’s GFR, calculated by the serum creatinine level prior to the present hospitalization on the background of a satisfactory condition.
Results. At admission to the hospital, in group 1 CKD progression was established in 33,3% of patients, in group 2 — in 29,3%. On the 10th day, CKD progression was noted in 47,4% of patients in group 1, in group 2 — in 23,4%.
Conclusion. The prevention program allows to reduce the number of cases of CKD progression in patients with decompensation of CHF by 2 times.
About the Authors
V. V. DavydovRussian Federation
Barnaul
E. L. Arekhina
Russian Federation
Barnaul
References
1. Waldum-Grevbo B. What Physicians Need to Know About Renal Function in Outpatients with Heart Failure. Cardiology 2015;131:130-8. doi:10.1159/000381012.
2. Al-Naher A, Pirmohamed M, Wright D, et al. Renal function monitoring in heart failure — what is the optimal frequency? A narrative review. British J of clinical pharmacology. 2018;84(1):5-17. doi:10.1111/bcp.13434.
3. Shen W, Wilcox CS, Brater DC, et al. Sodium and fluid excretion with torsemide in healthy subjects is limited by the short diurenic actions. JAHA. 2017;6(10):e006135. doi:10.1161/JAHA.117.006135.
4. Mareev VYu, Fomin OV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment Cardiology. 2018;58(S6):8-158. (In Russ.) doi:10.18087/cardio.2475.
5. Kobalava ZhD, Villevalde SV, Bagmanova NKh, et al. The prevanlence of chronic kidney disease markers in arterial hypertension patients and relation with diabetes: results of epidemiological study KHRONOGRAPH. Russ J Cardiol. 2018;23(2):91-101. (In Russ.) doi:10.15829/1560-4071-2018-2-91-101.
6. Leonova E, Isajevs S, Rostoka E, et al. New 1,4-Dihydropyridines down-regulate nitric oxigen in animals with streptozotocin-induced mellitus and protect deoxyribonucleic acid against peroxynitrite action. Basic and Clinical Pharmacology and Toxicology. 2016;119(1):19-31. doi:10.1016/j.cbi.2014.06.027.
7. Evdokimova AG, Arcadieva GV, Evdokimov VV, et al. Combinet and organ-protective anti-hypertension therapy: possibilities of fixed combination of Nitrendipin and Enalapril. Medicinskij sovet. 2016;13:28-33. (In Russ.) doi:10.21518/2079-701X-2016-13-28-33.
8. Evdokimova AG, Kovalenko EV, Lozhkina MV, et al. Characteristics of diuretic therapy in chronic heart failure. Consilium Medicum. 2016;18(1):32-7. (In Russ.)
9. Samatov IYu, Veynberg AL, Mezhin AV, et al, Correction of hypernatremia in severely burned patients. Polytrauma. 2018;2:35-40. (In Russ.)
Review
For citations:
Davydov V.V., Arekhina E.L. Prevention of chronic kidney disease progression in patients with acute decompensation of chronic heart failure. Russian Journal of Cardiology. 2019;(3):76-81. (In Russ.) https://doi.org/10.15829/1560-4071-2019-3-76-81